We show that immune responses elicited to neoantigens can be identified through immunopeptidome profiling in this work.

Vaccination against tumor antigens is one method being explored to generate immune responses against tumors and may be particularly effective in conjunction with therapies currently in the clinic, such as checkpoint inhibition. Identification of antigens for use in a vaccine is the pinch point of this method. Using immunopeptidome profiling, we have narrowed a collection of published potential neoantigens to those presented by MHC class I in the CT26 mouse colorectal cancer cell line. These peptides were synthesized used to immunize BALB/c mice, and immunogenicity of the peptide mix was evaluated by ELISpot to assess IFN-γ responses in immunized mice. These experiments support a complete workflow for the selection of potential cancer neoantigens that experimentally exhibit both MHC presentation and immunogenicity.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Nyayapathy, S., Jones, R., Ford, M., et al. CT26 neoantigen presentation and immunogenicity. Poster presented at: American Association for Cancer Research Annual Meeting 2023; April 14-19, 2023.